Tarcocimab tedromer is under clinical development by Kodiak Sciences and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tarcocimab tedromer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tarcocimab tedromer overview

Tarcocimab tedromer is under development for the treatment of proliferative and non-proliferative diabetic retinopathy, wet age-related macular degeneration (AMD), choroidal neovascularization and diabetic macular edema and macular edema due to retinal vein occlusion. It is administered through the intravitreal route. It acts by targeting vascular endothelial growth factor (VEGF). The drug candidate is a bioconjugate comprising two components. The first component is a recombinant, full-length humanized anti-VEGF monoclonal antibody, the second component is a branched, optically clear phosphorylcholine biopolymer which is stably attached to the antibody and which is intended to augment the stability and residence time of the bioconjugate in the eye without compromising its anti-VEGF activity. It is developed based on the high science antibody biopolymer conjugate (ABC) platform.

Kodiak Sciences overview

Kodiak Sciences is a bio pharmaceutical company that develops therapies for treatment of chronic and high prevalence ophthalmic diseases. Its pipeline products portfolio includes KSI 301 an anti-VEGF biologic development, which offers wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy; KSI-501 an anti-IL6 and anti-VEGF bispecific biopolymer conjugate; and KSI-601 a triplet biopolymer conjugate, which treats dry age-related macular degeneration. Kodiak Sciences utilizes proprietary Antibody Biopolymer Conjugate (“ABC”) Platform, that combines biologics design with next generation phosphorylcholine biopolymers. It commercializes technology to both bio-pharmaceuticals and small molecules companies. The company operates in the US and Switzerland. Kodiak Sciences is headquartered in Palo Alto, California, the US.

For a complete picture of Tarcocimab tedromer’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.